Compare First Citizens BancShares Inc (FCNCA) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Smith & Nephew plc — how do they compare? First Citizens BancShares Inc trades at $2,145.92 (market cap $23.76B), while Smith & Nephew plc trades at $31.4 (market cap $12.81B). The key difference: First Citizens BancShares Inc is the larger of the two by market cap, and Smith & Nephew plc pays the higher dividend (2.54%). Which is the better fit depends on your goals.
| FCNCA | SNN | |
|---|---|---|
Market Cap | $23.76B | $12.81B |
Sector | Sector/Thematic | Health |
52-Week High | $2.20K | $38.70 |
52-Week Low | $1.64K | $28.73 |
Dividend Yield | 0.41% | 2.54% |
Enterprise Value | — | $15.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,133.72, up 3.47% on the day, with a neutral technical signal despite bullish moving averages. The company demonstrates strong fundamentals with a trailing P/E of 11.94 and consistent earnings beats, including a Q1 2026 EPS of $44.86 versus $39.56 expected. Recent strategic moves include plans to retire the Silicon Valley Bank brand and expand commercial banking capabilities in Q4 2026.
The outlook is supported by solid profitability with a 24.35% net income margin and a shareholder-friendly dividend. Key risks include margin pressure and credit risk exposure from the legacy SVB portfolio. Analyst consensus is cautious with an 81.82% hold rating, though the consensus price target of $2,320 suggests modest upside from current levels.
Smith & Nephew (SNN) trades at $29.83, down 4.02% today, with a bearish technical signal. The company reported revenue of $5.81 billion in 2024, with net income of $412 million, showing improved profitability. Recent news highlights product launches in robotics and wound care, supported by a $500 million share buyback. Analyst consensus is mixed, with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility.
Outlook is balanced: strong free cash flow and innovation in medical technology offer growth potential, but near-term risks include competitive pressures and debt levels. The stock's valuation at a P/E of 21.51 is reasonable if earnings growth sustains, yet technical weakness suggests caution. Investors should weigh solid fundamentals against market sentiment and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
